The Impact of Isoniazid Preventive Therapy on Tuberculosis Infection and Disease Progression
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciag483 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Oscar E Zazueta und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Isoniazid, Antitubercular Agents, Tuberculosis, Tuberculosis, Pulmonary. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Center for Excellence in Translational Research, National Institute of Allergy and Infectious Diseases, Tuberculosis Research Unit.
Abstract (Originalsprache)
Background
Tuberculosis (TB) causes major morbidity and mortality among children worldwide. Isoniazid preventive therapy (IPT) protects against progression to TB disease, but its effect on preventing new TB infection remains uncertain.
Methods
We conducted a longitudinal cohort study in Lima, Peru, enrolling adults with microbiologically confirmed pulmonary TB and their household contacts (HHCs). We assessed HHCs at baseline and 6 months for TB infection using tuberculin skin testing (TST) and for TB disease through clinical evaluation. We assessed 2 outcomes in relation to IPT initiation: TB infection among HHCs under 5 years of age, indicated by an increase in TST induration of ≥6 mm from baseline to 6 months, and progression to TB disease among HHCs of all ages, diagnosed between 15 days and 12 months after enrollment.
Results
Among 666 under-5-year-olds included assessed for TST conversion, 361 (54.2%) had initiated IPT. Overall, 103 (15.5%) converted at 6 months; IPT initiation was not associated with conversion (adjusted OR 1.01; 95% CI, .64–1.59). Index participant cavitary disease was associated with an increased risk of conversion. In contrast, IPT initiation was associated with reduced risk of progression to TB disease among 14 032 HHCs of all ages (adjusted HR 0.45; 95% CI, .32–.64) with more pronounced efficacy among under-5 seconds (adjusted HR 0.19; 95% CI, .10–.36).
Conclusions
Isoniazid preventive therapy was not associated with reduced TST conversion among children under 5 years, but it was strongly associated with reduced progression to TB disease among HHCs of all ages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- School of Social Work, University of South Florida, Tampa, Florida, USA.
- Facultad de Medicina Humana, Universidad de San Martín de Porres, Lima, Peru.
- Socios En Salud, Lima, Peru.
- Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Oscar E Zazueta, Judith Jimenez, Leonid W Lecca, Megan B Murray
Förderung
- Center for Excellence in Translational Research
- National Institute of Allergy and Infectious Diseases
- Tuberculosis Research Unit
- NIAID NIH HHS
- NIH
Zitieren
APA
Zazueta, O. E., Becerra, M. C., Galea, J. T., Calderon, R. I., Contreras, C., Huang, C. C., Jimenez, J., Lecca, L. W., Yataco, R. M., Zhang, Z., & Murray, M. B. (2026). The Impact of Isoniazid Preventive Therapy on Tuberculosis Infection and Disease Progression. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag483
Vancouver
Zazueta OE, Becerra MC, Galea JT, Calderon RI, Contreras C, Huang CC, et al. The Impact of Isoniazid Preventive Therapy on Tuberculosis Infection and Disease Progression. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag483
BibTeX
@article{Zazueta2026,
author = {Zazueta, Oscar E and Becerra, Mercedes C and Galea, Jerome T and Calderon, Roger I and Contreras, Carmen and Huang, Chuan-Chin and Jimenez, Judith and Lecca, Leonid W and Yataco, Rosa M and Zhang, Zibiao and Murray, Megan B},
title = {The Impact of Isoniazid Preventive Therapy on Tuberculosis Infection and Disease Progression},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag483}
}
EUVIMED